文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

新型预后标志物EHMT2通过调控HSPD1参与乳腺癌细胞增殖。

The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer.

作者信息

Kim Seon-Kyu, Kim Kwangho, Ryu Jea-Woon, Ryu Tae-Young, Lim Jung Hwa, Oh Jung-Hwa, Min Jeong-Ki, Jung Cho-Rok, Hamamoto Ryuji, Son Mi-Young, Kim Dae-Soo, Cho Hyun-Soo

机构信息

Korea Research Institute of Bioscience and Biotechnology, Daejeon 305‑333, Republic of Korea.

Korea Institute of Toxicology (KIT), Daejeon 34114, Republic of Korea.

出版信息

Int J Oncol. 2019 Jan;54(1):65-76. doi: 10.3892/ijo.2018.4608. Epub 2018 Oct 26.

DOI:10.3892/ijo.2018.4608
PMID:30365075
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6254934/
Abstract

Molecular classifications of breast cancer (BRC), such as human epidermal growth factor receptor 2 (HER2), luminal A and luminal B, have been developed to reduce unnecessary treatment by dividing patients with BRC into low‑ and high‑risk progression groups. However, these methods do not cover all of the pathological characteristics of BRC, and investigations into novel prognostic/therapeutic markers are thus continually required. In this study, we identified the overexpression of the histone methyltransferase, euchromatic histone‑lysine N‑methyltransferase 2 (EHMT2) in BRC samples (n=1,222) and normal samples (n=113) derived from the TCGA portal by performing a BRC tissue microarray. EHMT2 overexpression was clearly associated with a poor prognosis in multiple cohorts of patients with BRC (total, n=1,644). Furthermore, the knockdown of EHMT2 expression affected cell apoptosis via the downregulation and re‑localization of heat shock protein family D (Hsp60) member 1 (HSPD1). In addition, a statistically significant positive correlation between EHMT2 and HSPD1 expression was revealed in the clinical cohorts. On the whole, the findings of this study may assist the development of novel therapeutic strategies and provide a prognostic marker (EHMT2) for patients with BRC.

摘要

乳腺癌（BRC）的分子分类，如人表皮生长因子受体2（HER2）、管腔A型和管腔B型，已被开发出来，通过将BRC患者分为低风险和高风险进展组来减少不必要的治疗。然而，这些方法并未涵盖BRC的所有病理特征，因此持续需要对新的预后/治疗标志物进行研究。在本研究中，我们通过制作BRC组织微阵列，确定了来自TCGA数据库的BRC样本（n = 1222）和正常样本（n = 113）中组蛋白甲基转移酶——常染色质组蛋白赖氨酸N - 甲基转移酶2（EHMT2）的过表达。EHMT2过表达与多个BRC患者队列（总计n = 1644）的不良预后明显相关。此外，EHMT2表达的敲低通过热休克蛋白家族D（Hsp60）成员1（HSPD1）的下调和重新定位影响细胞凋亡。此外，在临床队列中，EHMT2与HSPD1表达之间显示出具有统计学意义的正相关。总体而言，本研究结果可能有助于开发新的治疗策略，并为BRC患者提供一种预后标志物（EHMT2）。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4d/6254934/65b07cae1288/IJO-54-01-0065-g06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4d/6254934/c75c3c72c87b/IJO-54-01-0065-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4d/6254934/4cdd38f9271e/IJO-54-01-0065-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4d/6254934/9dbea6f6b252/IJO-54-01-0065-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4d/6254934/671df20a3f32/IJO-54-01-0065-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4d/6254934/ec7dae996ebd/IJO-54-01-0065-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4d/6254934/7f4a556e0e0d/IJO-54-01-0065-g05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4d/6254934/65b07cae1288/IJO-54-01-0065-g06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4d/6254934/c75c3c72c87b/IJO-54-01-0065-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4d/6254934/4cdd38f9271e/IJO-54-01-0065-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4d/6254934/9dbea6f6b252/IJO-54-01-0065-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4d/6254934/671df20a3f32/IJO-54-01-0065-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4d/6254934/ec7dae996ebd/IJO-54-01-0065-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4d/6254934/7f4a556e0e0d/IJO-54-01-0065-g05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4d/6254934/65b07cae1288/IJO-54-01-0065-g06.jpg

相似文献

[1]
The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer.

Int J Oncol. 2019-1

[2]
Inhibition of Euchromatic Histone Lysine Methyltransferase 2 (EHMT2) Suppresses the Proliferation and Invasion of Cervical Cancer Cells.

Cytogenet Genome Res. 2019

[3]
Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.

Anticancer Drugs. 2013-6

[4]
EHMT2 is a metastasis regulator in breast cancer.

Biochem Biophys Res Commun. 2018-2-5

[5]
Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1.

Neoplasia. 2011-8

[6]
Inhibition of EHMT2/G9a epigenetically increases the transcription of Beclin-1 via an increase in ROS and activation of NF-κB.

Oncotarget. 2016-6-28

[7]
RNA-seq based transcriptome analysis of EHMT2 functions in breast cancer.

Biochem Biophys Res Commun. 2020-2-4

[8]
BIX-01294 induces autophagy-associated cell death via EHMT2/G9a dysfunction and intracellular reactive oxygen species production.

Autophagy. 2013-12

[9]
EHMT2 Inhibition Induces Cell Death in Human Non-Small Cell Lung Cancer by Altering the Cholesterol Biosynthesis Pathway.

Int J Mol Sci. 2020-2-3

[10]
Knockdown of heat shock protein family D member 1 (HSPD1) promotes proliferation and migration of ovarian cancer cells via disrupting the stability of mitochondrial 3-oxoacyl-ACP synthase (OXSM).

J Ovarian Res. 2023-4-22

引用本文的文献

[1]
Decoding Hepatocellular Carcinoma Metastasis: Molecular Mechanisms, Targeted Therapies, and Potential Biomarkers.

Curr Issues Mol Biol. 2025-4-8

[2]
Comprehensive Analysis of the Role of Heat Shock Proteins in the Immune Microenvironment and Clinical Significance of Hepatocellular Carcinoma.

J Hepatocell Carcinoma. 2025-2-17

[3]
Integrating single-cell sequencing and machine learning to uncover the role of mitophagy in subtyping and prognosis of esophageal cancer.

Apoptosis. 2025-4

[4]
Multi-omics joint screening of biomarkers related to M2 macrophages in gastric cancer.

Discov Oncol. 2024-12-2

[5]
Addressing the mean-variance relationship in spatially resolved transcriptomics data with .

bioRxiv. 2024-11-8

[6]
Cellulose Nanofibrils of High Immunoaffinity for Efficient Enrichment of Small Extracellular Vesicles.

Small Methods. 2024-11

[7]
Molecular analysis to identify novel potential biomarkers as drug targets in colorectal cancer therapy: an integrated bioinformatics analysis.

Mol Cell Oncol. 2024-3-18

[8]
6-Formylindolo[3,2-b]carbazole, a potent ligand for the aryl hydrocarbon receptor, attenuates concanavalin-induced hepatitis by limiting T-cell activation and infiltration of proinflammatory CD11b+ Kupffer cells.

J Leukoc Biol. 2024-5-29

[9]
Anticancer Effects of Gut Microbiota-Derived Short-Chain Fatty Acids in Cancers.

J Microbiol Biotechnol. 2023-7-28

[10]
Investigating the Function of Human Jumping Translocation Breakpoint Protein (hJTB) and Its Interacting Partners through In-Solution Proteomics of MCF7 Cells.

Molecules. 2022-11-28

本文引用的文献

[1]
Interleukin-2 induces the in vitro maturation of human pluripotent stem cell-derived intestinal organoids.

Nat Commun. 2018-8-2

[2]
Comparative in silico profiling of epigenetic modifiers in human tissues.

Mol Biol Rep. 2018-6

[3]
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.

Cell. 2018-4-5

[4]
Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC.

Oncotarget. 2017-12-14

[5]
Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine.

Semin Cancer Biol. 2018-1-12

[6]
EHMT2 is a metastasis regulator in breast cancer.

Biochem Biophys Res Commun. 2018-2-5

[7]
and imaging and tracking of intestinal organoids from human induced pluripotent stem cells.

FASEB J. 2017-8-29

[8]
G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin.

Nat Commun. 2017-8-17

[9]
A liver-specific gene expression panel predicts the differentiation status of in vitro hepatocyte models.

Hepatology. 2017-11

[10]
Plasma glutamate carboxypeptidase is a negative regulator in liver cancer metastasis.

Oncotarget. 2016-11-29

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索